The differentiation-promoting potential of a cytostatic fluoro-pyranosyl adriamycin analog (FAD 104).
Acute toxicity to the hematopoietic cell renewal system is a critical side effect of most anticancer agents. Here we compared the effects of FAD-104 to those of the parent compound adriamycin (ADM) and of epi-adriamycin (epi-ADM) on the growth and differentiation of normal as well as leukemic human myeloid progenitor cells. FAD-104 was less toxic to myeloid colony-forming cells (GM-CFU) than ADM or epi-ADM. In addition, FAD-104 but not ADM induced a clonal down-grading in both normal and leukemic blast cells, and it stimulated the terminal differentiation of myeloid leukemia cells. Therefore, FAD-104 may be useful in the treatment of some forms of myeloid leukemia.
Blazsek
I
I
Institut du Cancer et d'Immunogénétique (Univ. Paris-Sud, Association Claude-Bernard & ARC), Hôpital Paul-Brousse, Villejuif, France.
Mathé
G
G
Comisso
M
M
Kitasato
H
H
Umezawa
K
K
Umezawa
H
H
D000970:Antineoplastic Agents / Q000633:toxicity*; D001853:Bone Marrow / Q000473:pathology*; D003114:Colony-Forming Units Assay; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000633:toxicity; D006412:Hematopoietic Stem Cells / Q000187:drug effects*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000473:pathology
D000970:Antineoplastic Agents; C059081:ME 2303; D004317:Doxorubicin